AURKA and medulloblastoma: In vitro treatment of GTML/Trp53KI/KI medulloblastoma-derived neurospheres with the Aurora-A kinase inhibitor MLN8237 (Alisertib) destabilized MYCN via disruption of the Aurora-A/MYCN complex and caused growth inhibition comparable to doxycycline-mediated genetic suppression of MYCN expression (Figure 4A; Figures S4A–S4C).